Modality
ASO
MOA
Cl18.2
Target
TROP-2
Pathway
Autophagy
Ovarian Ca
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
~Aug 2017
→ ~Nov 2018
NDA/BLA
Feb 2019
→ Jan 2025
NDA/BLACurrent
NCT05181412
2,627 pts·Ovarian Ca
2019-02→2025-01·Not yet recruiting
2,627 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2025-01-281.2y agoPh3 Readout· Ovarian Ca
Trial Timeline
2019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2025-01-28 · 1.2y ago
Ovarian Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05181412 | NDA/BLA | Ovarian Ca | Not yet recr... | 2627 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-4076 | Novartis | Preclinical | TROP-2 | |
| NVS-8902 | Novartis | Preclinical | TROP-2 | |
| Zorivorutinib | Bristol-Myers Squibb | Approved | DLL3 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| ION-1378 | Ionis | NDA/BLA | TROP-2 | |
| HAL-9635 | Halozyme | Phase 2/3 | EZH2 | |
| Nirafotisoran | Jazz Pharma | Phase 2/3 | TROP-2 | |
| ILM-4317 | Illumina | NDA/BLA | TROP-2 | |
| VKT-6548 | Viking Therapeutics | Phase 2/3 | PD-L1 |